19:37 , May 6, 2019 |  BC Extra  |  Company News

May 6 Company Quick Takes: Esperion, BioMarin, WuXi AppTec, Axsome, Harbour BioMed/CTTQ, GW, Adynxx

FDA accepts Esperion NDAs for LDL-C-lowering indications  Esperion Therapeutics Inc. (NASDAQ:ESPR) gained $5 (12%) to $48.24 on Monday after FDA accepted for review a pair of NDAs for bempedoic acid (ETC-1002) and a bempedoic acid/ezetimibe...
21:58 , Apr 26, 2019 |  BioCentury  |  Product Development

Rise of the independents, biotechs go to market

While product launch and commercialization has largely been the province of big biotech and big pharma, with smaller companies partnering to get their products over the finish line, BioCentury’s analysis of recent FDA approvals finds...
23:08 , Apr 15, 2019 |  BC Extra  |  Company News

Management tracks: GW Pharmaceuticals, Aurinia

Cannabinoid company GW Pharmaceuticals plc (NASDAQ:GWPH) hired Darren Cline as chief commercial officer. He succeeds Julian Gangolli who is retiring. Cline was EVP, commercial at Seattle Genetics Inc. (NASDAQ:SGEN). Aurinia Pharmaceuticals Inc. (TSX:AUP; NASDAQ:AUPH) hired...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
12:44 , Mar 27, 2019 |  BioCentury  |  Product Development

GW’s next act

As Epidiolex’s launch continues to ramp up, GW Pharmaceuticals’ next act will be to take the plunge with its cannabinoid platform into larger, more complex neurobehavioral indications, and even cancer. Not surprisingly, the rise of...
21:35 , Mar 18, 2019 |  BC Extra  |  Company News

Biohaven spends $105M for faster review of oral CGRP inhibitor

Biohaven bought a $105 million Priority Review voucher from GW Pharmaceuticals to expedite the entry of its oral migraine therapy into the CGRP inhibitor market. It plans to use the voucher on an NDA for...
01:36 , Mar 1, 2019 |  BC Week In Review  |  Company News

GW gains on first sales figure for Epidiolex

GW Pharmaceuticals plc (NASDAQ:GWPH) added $21.10 (14%) to $173.99 on Feb. 27 after reporting that sales of Epidiolex cannabidiol reached $4.7 million in the two-month period since the marijuana-derived drug's launch on Nov. 1. FDA...
19:53 , Feb 27, 2019 |  BC Extra  |  Company News

GW gains on first sales figure for Epidiolex

GW Pharmaceuticals plc (NASDAQ:GWPH) added $21.10 (14%) to $173.99 on Wednesday after reporting that sales of Epidiolex cannabidiol reached $4.7 million in the two-month period since the marijuana-derived drug's launch on Nov. 1. FDA approved...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...